A Multi-center, Prospective, Non-interventional (ni) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors

Trial Profile

A Multi-center, Prospective, Non-interventional (ni) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 29 Jun 2017 Planned End Date changed from 1 Nov 2022 to 30 Nov 2022.
    • 29 Jun 2017 Planned primary completion date changed from 1 Nov 2022 to 30 Nov 2022.
    • 28 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top